 CONCORD, Calif.--BUSINESS WIRE--Cerus Corporation Nasdaq: CERS today announced that the U.S. Centers for Medicare Medicaid Services CMS has granted a new technology add-on payment NTAP for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System IPPS. The NTAP was granted under CMS alternative NTAP pathway, which recognizes the transformative nature of products granted Breakthrough Device designation by the U.S. Food and Drug Administration 